tirzepatide adverse events as Compared with Semaglutide for the Treatment of Obesity Gastrointestinal adverse events and weight

Not everyone with NAFLD will experience the same liver benefit, so physicians must monitor individual outcomes and modify strategies accordingly

M.GudzuneK

Sales of obesity drugs including Wegovy increased by 56%, taking total sales 16% higher to 155bn Danish kroner (18bn)

The current results show that number needed to benefit (NNTB) was 207 (95%CI: NNTB 129 to NNTB 620, Follow-up time: 3.48 1.51 years) for total MI, NNTB 67 (95%CI: NNTB 46 to NNTB 135, Follow-up time: 3.48 1.51 years) for MACE, NNTB 170 (95%CI: NNTB 120 to NNTB 306, Follow-up time: 3.48 1.51 years) for cardiovascular mortality, and NNTB 93 (95%CI: NNTB 52 to NNTB 1717, Follow-up time: 3.45 1.21 years) for coronary revascularization

Supplementation does not seem to increase muscle carnitine in almost all situations

While precise current user numbers vary by data source, IQVIA tracking shows substantial year-over-year growth, though supply constraints and insurance coverage limitations continue to affect access